Stevanato Group (STVN) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue grew 2% year-over-year to €260 million, driven by 9% growth in the BDS segment and 23% growth in high-value solutions, now 40% of total revenue, offset by a 26% decline in Engineering due to project delays and higher costs.

• Margins were pressured by higher costs, Engineering execution challenges, vial destocking, and start-up inefficiencies in new facilities in Fishers and Latina.

• The company is executing operational improvements, consolidating Danish operations, and standardizing processes to address project delays and cost overruns.

• Ongoing capacity expansions in the U.S. and Italy, with commercial production at Fishers expected in Q3 2024 and Latina expansion ongoing.

• Long-term fundamentals remain strong, with robust demand for high-value solutions and healthy end-markets, especially in biologics.

Financial highlights

• Q2 2024 revenue: €260 million, up 2% year-over-year; high-value solutions revenue up 23% to €103.4 million, now 40% of total revenue.

• Gross profit margin decreased to 26% from 30.9% year-over-year, mainly due to higher Engineering costs, vial destocking, and start-up inefficiencies.

• Operating profit margin fell to 10.8% (adjusted: 12.8%); net profit: €20.6 million; adjusted net profit: €24.5 million; adjusted diluted EPS: €0.09.

• Adjusted EBITDA: €54 million; adjusted EBITDA margin: 20.8%.

• Free cash flow was negative €46.1 million in Q2 2024, impacted by €75.9 million in capital expenditures.

Outlook and guidance

• Fiscal 2024 revenue expected between €1,090 million and €1,110 million, with adjusted EBITDA guidance of €264–272 million and adjusted diluted EPS of €0.48–0.50.

• Guidance revision driven by ongoing Engineering Segment challenges, with Engineering revenue projected to decline 15–20% for 2024.

• BDS segment expected to see mid-single-digit growth, with high-value solutions comprising 36%–40% of 2024 revenue.

• CapEx for 2024 maintained at €300–335 million; tax rate at 25%.

• Positive momentum in high-value solutions expected to continue, but vial recovery and Engineering improvements may temper near-term growth.